Cancer marker diagnostics

MicroSight® MSI

Microsatellite instability (MSI) is a genomic alteration in the length of microsatellites provoked by a deficient DNA mismatch repair system. MSI is known to occur in several types of cancer e.g., colorectal cancer (CRC), which accounts for 10.7% of newly diagnosed cancers globally (3’rd most occurring) according to World Cancer Research Fund’s data (2020). Identification of MSI in tumours is important as a predictive factor of response to different therapies, in particular to immune checkpoint inhibitors, and accordingly the need for MSI analysis of these patients has significantly increased. The MicroSight® MSI 1-step HRM Analysis assay analyses five well-described mononucleotide microsatellite sequences: BAT25, BAT26, NR22, NR24, and MONO27, by Real-Time PCR and HRM. The assay evaluates microsatellite length of patient tumour DNA to patient non-tumour DNA or a universal reference, which makes it a valuable stratification tool for assisting cancer treatment planning. After the Real-Time PCR and HRM, a semi-automatic analysis will be made by the instrument software giving objective results in less than 2 hours.

PlentiPlex™ MSI

PlentiPlex™ MSI assays are intended for evaluation of impaired mismatch repair (MMR) and the resulting microsatellite instability affecting prognosis and selection of treatment in cancer patients. PlentiPlex™ MSI assays offer two different multiplexed MSI assays for the length analysis of five microsatellite loci. This makes PlentiPlex™ MSI assays valuable stratification tools for assisting cancer treatment planning.

SensiScreen®

Common cancers including colorectal cancer, lung cancer and malignant melanoma are characterized by the accumulation of somatic mutations, some of which  are known to affect a patient’s response to cancer treatments. SensiScreen® qPCR-based assays provide fast and reliable somatic mutation detection to support rapid initiation of the optimal cancer treatment. The assay is available in 2 formats: Analysis of liquid biopsies / Analysis of FFPE biopsies.

PlentiPlex™ Mastocytosis

PlentiPlex™ Mastocytosis assay is intended for the detection of the KIT D816V mutation, which is among the WHO criteria for the diagnosis of mastocytosis. PlentiPlex™ Mastocytosis Assay utilises PentaBase’s unique DNA chemistry, known as Intercalating Nucleic Acid (INA™), which vastly increases both affinity and specificity of assay oligonucleotides towards the target region compared to assays based on standard DNA chemistries. PlentiPlex™ Mastocytosis follows WHO criteria and is applicable for large biopsies. The assay is available in 2 formats: Ready-to-use / Dispense ready. Enables further personalised cancer treatment.

PlentiPlex™ MYD88

PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay utilises PentaBase’s unique DNA chemistry, known as Intercalating Nucleic Acid (INA™) which vastly increases both affinity and specificity of assay oligonucleotides towards the target region compared to assays based on standard DNA chemistries.
The obtained results of PlentiPlex™ MYD88 Waldenström Lymphoma qPCR Assay are intended for identification of the presence of the MYD88 L265P, facilitating discrimination between Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia (LPL/WM) and non-Hodgkin lymphoma